Dose intensity analysis in advanced ovarian cancer patients.

about

First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence The evidence for increasing cytotoxic dose intensity in the treatment of advanced ovarian cancer.

P2860

Q36115739-1F076F01-CC3D-4AFC-B37A-5D530F45088A Q40643516-23A031FA-5B22-4D6F-A84E-BC4ACB8D4570

P2860

Dose intensity analysis in advanced ovarian cancer patients.

Item

http://www.wikidata.org/entity/Q35975958

description

1993 nî lūn-bûn

@nan

1993年の論文

@ja

1993年論文

@yue

1993年論文

@zh-hant

1993年論文

@zh-hk

1993年論文

@zh-mo

1993年論文

@zh-tw

1993年论文

@wuu

1993年论文

@zh

1993年论文

@zh-cn

name

Dose intensity analysis in advanced ovarian cancer patients.

@ast

Dose intensity analysis in advanced ovarian cancer patients.

@en

type

Item

label

Dose intensity analysis in advanced ovarian cancer patients.

@ast

Dose intensity analysis in advanced ovarian cancer patients.

@en

prefLabel

Dose intensity analysis in advanced ovarian cancer patients.

@ast

Dose intensity analysis in advanced ovarian cancer patients.

@en

P1476

Dose intensity analysis in advanced ovarian cancer patients.

@en

P2093

Korn EL

http://www.w3.org/2001/XMLSchema#string

Simon R

http://www.w3.org/2001/XMLSchema#string

Torri V

http://www.w3.org/2001/XMLSchema#string

P2860

Dose-response effect of adjuvant chemotherapy in breast cancer

Meta-analysis in clinical research

A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group.

Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin.

A prospective randomized clinical trial of melphalan and cis-platinum versus hexamethylmelamine, adriamycin, and cyclophosphamide in advanced ovarian cancer.

High dose cisplatin compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages III and IV): report from the North Thames Cooperative Group.

Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease

The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma.

Common epithelial cancer of the ovary (2).

Dose-response in the treatment of breast cancer: a critical review.

P2888

bjc.1993.33

P304

190-197

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1038/BJC.1993.33

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

1993-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14771089

http://www.w3.org/2001/XMLSchema#string

P698

8427779

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

1968241

http://www.w3.org/2001/XMLSchema#string

Dose intensity analysis in advanced ovarian cancer patients.

about

P2860

P2860

Dose intensity analysis in advanced ovarian cancer patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932